Talis Biomedical Corp expected to post a loss of $1.28 a share - Earnings Preview

Talis Biomedical

11/03/2022 22:11

* Talis Biomedical Corp  TLIS.OQ   TLIS.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 15. 
    * The Menlo Park California-based  company is expected to
report 
a 472.2% increase in revenue to $1.333 million from $233
thousand a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Talis Biomedical
Corp is
for a loss of $1.28 per share. For the same quarter last year,
the company reported a loss of $20.84 per share.
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Talis
Biomedical
Corp is $4.5​, above​ its last closing price of $1.75. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -1.38       -1.40      -1.49     Missed  -6.4
 Jun. 30 2021  -0.91       -0.91      -2.51     Missed  -175.1
 Mar. 31 2021  -0.75       -0.75      -4.61     Missed  -514.7
                                                        ​
 Dec. 31 2020  -0.78       -0.78      -20.84    Missed  -2,554
                                                        .8
 ​​                                                     
                                                        ​
 This summary was machine generated March 11 at 22:11 GMT.  All
figures in US dollars  unless otherwise stated